Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions

Brain Research

Volumn 1112, Issue 1, 2006, Pages 126-133

  Matsubara, Kazuo ^a   Shimizu, Keiko ^a   Suno, Manabu ^a   Ogawa, Kento ^a   Awaya, Toshio ^a   Yamada, Takehiro ^a   Noda, Toshihiro ^a   Satomi, Machiko ^a   Ohtaki, Ko ichi ^a   Chiba, Kaoru ^a   Tasaki, Yoshikazu ^a   Shiono, Hiroshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

5 HT1A receptor agonist; 6 Hydroxydopamine; 8 OHDPAT; Parkinson disease; Rotation behavior; Tandospirone; WAY 100635

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DESIPRAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; PARGYLINE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENTOPEDUNCULAR NUCLEUS; FRONTAL CORTEX; MAJOR DEPRESSION; MALE; MEDIAN RAPHE NUCLEUS; MOTOR DYSFUNCTION; NERVE CONDUCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SUBTHALAMIC NUCLEUS;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZAZEPINES; BRAIN INJURIES; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; ISOINDOLES; MALE; MOVEMENT DISORDERS; OXIDOPAMINE; PIPERAZINES; PYRIDINES; PYRIMIDINES; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; TIME FACTORS;

EID: 33748433364     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.07.003     Document Type: Article

References (61)

1. Ahlenius S., and Salmi P. Antagonism of reserpine-induced suppression of spontaneous motor activity by stimulation of 5-HT1A receptors in rats. Pharmacol. Toxicol. 76 (1995) 149-156
2. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 (1989) 366-375
3. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.S.t., Penney J.B., and Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 46 (1992) 35-48
4. Bergman H., Wichmann T., and DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990) 1436-1438
5. Biggs C.S., Fowler L.J., Whitton P.S., and Starr M.S. Extracellular levels of glutamate and aspartate in the entopeduncular nucleus of the rat determined by microdialysis: regulation by striatal dopamine D2 receptors via the indirect striatal output pathway?. Brain Res. 753 (1997) 163-175
6. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 20 (2005) 919-931
7. Burnet P.W., Eastwood S.L., Lacey K., and Harrison P.J. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 676 (1995) 157-168
8. Carpenter M.B., and Carpenter C.S. Analysis of somatotropic relations of the corpus luysi in man and monkey; relation between the site of dyskinesia and distribution of lesions within the subthalamic nucleus. J. Comp. Neurol. 95 (1951) 349-370
9. de Groote C., Wullner U., Lochmann P.A., Luiten P.G., and Klockgether T. Functional characterization and expression of thalamic GABA(B) receptors in a rodent model of Parkinson's disease. Neuropharmacology 38 (1999) 1683-1689
10. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 (1990) 281-285
11. Dijk S.N., Francis P.T., Stratmann G.C., and Bowen D.M. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br. J. Pharmacol. 115 (1995) 1169-1174
12. Eison M.S. The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 22 (1989) 13-20
13. Elliott P.J., Walsh D.M., Close S.P., Higgins G.A., and Hayes A.G. Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology 29 (1990) 949-956
14. Feighner J.P., and Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 22 (1989) 21-26
15. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M., and Del Rio J. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 (2001) 288-296
16. Fujino Y., Nakajima M., Tsuboi Y., Baba Y., and Yamada T. Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy. Rinsho Shinkeigaku 42 (2002) 42-44
17. Galeffi F., Bianchi L., Bolam J.P., and Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 18 (2003) 856-868
18. Glennon R.A., and Lucki I. Behavioral models of serotonin receptor activation. In: Sanders-Bush E. (Ed). The Serotonin Receptors (1988), Humana Press, Clifton 253-293
19. Godbout R., Chaput Y., Blier P., and de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine: I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology 30 (1991) 679-690
20. Guridi J., and Obeso J.A. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 124 (2001) 5-19
21. Halliday G.M., Blumbergs P.C., Cotton R.G., Blessing W.W., and Geffen L.B. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510 (1990) 104-107
22. Hamik A., Oksenberg D., Fischette C., and Peroutka S.J. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatry 28 (1990) 99-109
23. Handley S.L., and McBlane J.W. 5HT drugs in animal models of anxiety. Psychopharmacology 112 (1993) 13-20
24. Harrington M.A., Oksenberg D., and Peroutka S.J. 5-Hydroxytryptamine 1A receptors are linked to a Gi-adenylate cyclase complex in rat hippocampus. Eur. J. Pharmacol. 154 (1988) 95-98
25. Herrera-Marschitz M., Hyttel J., and Ungerstedt U. The dopamine D-1 antagonist SCH 23390 inhibits apomorphine but not pergolide induced rotation. Acta Physiol. Scand. 122 (1984) 427-428
26. Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47 (1990) 1609-1615
27. Hudson J.L., Levin D.R., and Hoffer B.J. A 16-channel automated rotometer system for reliable measurement of turning behavior in 6-hydroxydopamine lesioned and transplanted rats. Cell Transplant. 2 (1993) 507-514
28. Invernizzi R.W., Cervo L., and Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27 (1988) 515-518
29. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease. Curr. Opin. Invest. Drugs 5 (2004) 720-726
30. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., and Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54 (2002) 133-137
31. Klockgether T., and Turski L. NMDA antagonists potentiate antiparkinsonian actions of l-dopa in monoamine-depleted rats. Ann. Neurol. 28 (1990) 539-546
32. Levesque J.C., and Parent A. GABAergic interneurons in human subthalamic nucleus. Mov. Disord. 20 (2005) 574-584
33. Maeda T., Kannari K., Suda T., and Matsunaga M. Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum. Brain Res. 817 (1999) 185-191
34. Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L., and Morari M. Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. a dual probe microdialysis study in hemiparkinsonian rats. Eur. J. Neurosci. 12 (2000) 1848-1850
35. McGeorge A.J., and Faull R.L. The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29 (1989) 503-537
36. Miyata S., Hamamura T., Yoshinaga J., Nakamura Y., Imamura T., Hikiji A., and Kuroda S. Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to l-threo-3,4-dihydroxyphenylserine. Clin. Neuropharmacol. 24 (2001) 232-234
37. Neal-Beliveau B.S., Joyce J.N., and Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265 (1993) 207-217
38. Nishitsuji K., To H., Shimizu T., Yanase Y., Yamada T., Hara C., Mine K., and Higuchi S. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur. Neuropsychopharmacol. 16 (2006) 376-382
39. Patane M.A., DiPardo R.M., Price R.P., Chang R.S., Ransom R.W., O'Malley S.S., Di Salvo J., and Bock M.G. Selective alpha-1a adrenergic receptor antagonists. Effects of pharmacophore regio- and stereochemistry on potency and selectivity. Bioorg. Med. Chem. Lett. 8 (1998) 2495-2500
40. Paxions G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. (1986), Academic Press, Sydney
41. Perry K.W., and Fuller R.W. Determination of brain concentrations of 8-hydroxy-2-(di-n-propylamino)tetralin by liquid chromatography with electrochemical detection. Biochem. Pharmacol. 38 (1989) 3169-3173
42. Prow M.R., Martin K.F., and Heal D.J. 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterization. Eur. J. Pharmacol. 317 (1996) 21-28
43. Sandyk R., and Fisher H. Serotonin in involuntary movement disorders. Int. J. Neurosci. 42 (1988) 185-208
44. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
45. Shimizu H., Hirose A., Tatsuno T., Nakamura M., and Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn. J. Pharmacol. 45 (1987) 493-500
46. Shimizu H., Karai N., Hirose A., Tatsuno T., Tanaka H., Kumasaka Y., and Nakamura M. Interaction of SM-3997 with serotonin receptors in rat brain. Jpn. J. Pharmacol. 46 (1988) 311-314
47. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19 (1995) 264-293
48. Tanaka H., Tatsuno T., Shimizu H., Hirose A., Kumasaka Y., and Nakamura M. Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen. Pharmacol. 26 (1995) 1765-1772
49. Tatsuno T., Shimizu H., Hirose A., Tanaka H., Kumasaka Y., and Nakamura M. Effects of the putative anxiolytic SM-3997 on central monoaminergic systems. Pharmacol. Biochem. Behav. 32 (1989) 1049-1055
50. Tomiyama M., Kimura T., Maeda T., Kannari K., Matsunaga M., and Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease. Neurosci. Res. 52 (2005) 185-194
51. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol. Toxicol. 69 (1991) 149-156
52. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs 17 (2003) 475-489
53. Van Praag H.M. 5-HT-related, anxiety- and/or aggression-driven depression. Int. Clin. Psychopharmacol. 9 (1994) 5-6
54. Veazey C., Aki S.O., Cook K.F., Lai E.C., and Kunik M.E. Prevalence and treatment of depression in Parkinson's disease. J. Neuropsych. Clin. Neurosci. 17 (2005) 310-323
55. Wadenberg M.L., and Hillegaart V. Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34 (1995) 495-499
56. Watanabe H., Arahata Y., Tadokoro M., Kato T., and Sobue G. Effects of tandospirone citrate on frozen gait in patients with early stage of progressive supranuclear palsy, investigated by walk-induced activation single photon emission computed tomography method. Rinsho Shinkeigaku 40 (2000) 1130-1132
57. Wieland S., and Lucki I. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101 (1990) 497-504
58. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., and Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 351 (1995) 357-373
59. Yoshino T., Nisijima K., Katoh S., Yui K., and Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem. Int. 40 (2002) 355-360
60. Yu, H., Lewander, T., 1997. Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. 7, 165-172.
61. Yu Y., Ramage A.G., and Koss M.C. Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats. Eur. J. Pharmacol. 489 (2004) 207-213